Prospective, Multi-center, Single-arm, Open-label Long-term Study Assessing the Safety, Tolerability, and Effectiveness of Macitentan in Fontan-palliated Adult and Adolescent Subjects
Latest Information Update: 09 Mar 2023
At a glance
- Drugs Macitentan (Primary)
- Indications Congenital heart defects
- Focus Adverse reactions
- Acronyms RUBATO OL
- Sponsors Actelion Pharmaceuticals
- 06 Mar 2023 Status has been changed to discontinued.
- 26 Oct 2021 Planned End Date changed from 8 Sep 2023 to 17 Jan 2022.
- 26 Oct 2021 Planned primary completion date changed from 30 Jul 2023 to 17 Jan 2022.